Oral insulin - a review of current status

Diabetes, Obesity and Metabolism

Volumn 12, Issue 3, 2010, Pages 179-185

  Iyer, Harish ^a   Khedkar, Anand ^a   Verma, Manish ^a  

^a Biocon Limited   (India)

Author keywords

Alternate routes of insulin delivery; Hepatic insulin delivery; Oral insulin; Physiological insulin delivery; Portal insulin delivery

Indexed keywords

ALGINIC ACID; BACITRACIN; BETA CYCLODEXTRIN; BILE SALT; CAMOSTAT MESILATE; CAPSULIN; CARBOXYPEPTIDASE; CHITOSAN; CHOLIC ACID; CHYMOTRYPSIN; CYANOACRYLATE; ELIGEN; FATTY ACID; GLUCOSE; GLYCOCHOLATE SODIUM; HEXYL INSULIN MONOCONJUGATE 2; HEXYLRESORCINOL; IN 105; INSULIN; INTESULIN; LIPOSOME; MACROGOL; METFORMIN; OCCLUDIN; ORAL ANTIDIABETIC AGENT; PANCREATIN; PEPSIN A; PLACEBO; POLYGLACTIN; TRYPSIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIET THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG TOLERABILITY; EARLY INTERVENTION; ENCAPSULATION; ENTERIC COATED TABLET; GASTROINTESTINAL SECRETION; GLYCEMIC CONTROL; HEALTH CARE NEED; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; TECHNOLOGY; TREATMENT DURATION; WEIGHT GAIN;

EID: 75649094914     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01150.x     Document Type: Review

References (64)

1. Mahler RJ, Adler ML. Type 2 diabetes mellitus: update on diagnosis, pathophysiology and treatment. J Clin Endocrinol Metab 1999, 84:1165-1171.
2. Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009, 32:1-11.
3. Funnell MM. The Diabetes Attitudes, Wishes and Needs (DAWN) study. Clin Diabetes 2006, 24:154-155.
4. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007 2008, Centers for Disease Control and Prevention, Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention
5. Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl. 1):S12-S54. American Diabetes Association
6. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 1982, 5:353-363.
7. Zhao L, Sun D, Cao F, Yin T, Wang H. Can insulin resistance be reversed by insulin therapy? Med Hypotheses 2009, 72:34-35. [Epub 2008].
8. Romano G, Patti L, Innelli F. Insulin and sulfonylurea therapy in NIDDM patients. Are the effects on lipoprotein metabolism different even with similar blood glucose control? Diabetes 1997, 46:1601-1606.
9. Nathan DM, Roussell A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: a randomized double-blind study. Ann Intern Med 1988, 108:334-340.
10. Li Y, Xu W, Liao Z. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care 2004, 27:2597-2602.
11. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
12. Ilkova H, Glaser B, Tunckale A. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1353-1356.
13. Weng J, Li Y, Xu W. Effect of intensive insulin therapy on beta-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 2008, 371:1753-1760.
14. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589. Prospective Diabetes UK Study (UKPDS) Group
15. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. The Action to Control Cardiovascular Risk in Diabetes Study Group
16. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE Collaborative Group
17. Saaddinne JB, Cadwell B, Gregg EB. Improvements in diabetes processes of care and intermediate outcomes: United States 1988-2002. Ann Intern Med 2006, 144:465-474.
18. Heinemann L, Jacques Y. Oral insulins and buccal insulins: a critical repraisal. J Diabetes Sci Technol 2009, 3:568-584.
19. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004, 6:510-517.
20. Stratton IM, Adler AI, Neil HAW. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
21. Escandon JC, Robbins DC. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 1987, 36:1167-1172.
22. Pianta D, Mari A, Valerio A. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999, 48:99-105.
23. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28:187-218.
24. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008, 31:1927-1932.
25. Ergun-Longmire B, Marker J, Zeidler A. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann N Y Acad Sci 2004, 1029:260-277.
26. Skyler JS, Krischer JP, Wolfsdorf J. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005, 28:1353-1357.
27. Bergerot I, Arreaza GA, Cameron MJ. Insulin B-chain reactive CD 4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. Diabetes 1999, 48:1720-1729.
28. Weiner HL. Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 1997, 48:341-351.
29. Wang W. Oral protein delivery. J Drug Target 1996, 4:195-232.
30. Carino GP, Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999, 35:249-257.
31. Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 1994, 11:61-95.
32. Pappo J, Ermak TH. Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: a quantitative model for M cell uptake. Clin Exp Immunol 1989, 76:144-148.
33. Aspden TJ, Mason JD, Jones NS. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997, 86:509-513.
34. Mathiowitz E, Jacob JS, Jong YS. Biologically erodible microspheres as potential oral drug delivery systems. Nature 1997, 386:410-414.
35. Damge C, Michael C, Aprahamian M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as oral carrier. Diabetes 1988, 37:247-251.
36. Takka S, Acarturk F. Calcium alginate microparticles for oral administration. I: effect of sodium alginate type on drug release and drug entrapment efficiency. J Microencapsul: Micro Nano Carriers 1999, 16:275-290.
37. Rowsen Moses L, Dileep KJ, Sharma CP. Beta cyclodextrin-insulin-encapsulated chitosan/alginate matrix: oral delivery system. J Appl Polym Sci 2000, 75:1089-1096.
38. Dapergolas G, Gregoriadis G. Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats. Lancet 1976, 2:824-827.
39. Fasano A, Fiorentini C, Donelli G. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 1995, 96:710-720.
40. Mesiha M, Plakogiannis F, Vejosoth S. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions. Int J Pharm 1994, 111:213-216.
41. Abuchowski A, McCoy JR, Palczuk NC. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977, 252:3582-3586.
42. Hosny EA, Al-Shora HIa, Elmazar MMA. Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. Int J Pharm 2002, 237:71-76.
43. Lowman AM, Morishita M, Kajita M, Nagai T, Peppas NA. Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci 1999, 88:933-937.
44. Yamamoto A, Taniguchi T, Rikyuu K. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 1994, 11:1496-1500.
45. Clement S, Still JG, Kosutic G. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol Ther 2002, 4:459-466.
46. Palin KJ, Phillips AJ, Ning A. The oral absorption of cefoxitin from oil and emulsion vehicles in rats. Int J Pharm 1986, 33:99-104.
47. Fasano A, Uzzau S. Modulation of intestinal tight junctions zona occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 1997, 99:1158-1164.
48. Young LE, Phillips WA, Murlin JR. New results on the absorption of insulin from the alimentary tract. Am J Physiol 1939, 128:81-91.
49. Heise T, Kapitza C, Nosek L. Oral Insulin as First Line Therapy in Type 2 Diabetes: A Randomized-controlled Pilot Study [late-breaking abstract] 2004, Orlando, American Diabetes Association, 64th Scientific Sessions,
50. Emisphere's press release (October 6, 2006) on additional clinical data from phase 2 oral insulin trial. http://www.emisphere.com, SOURCE Emisphere Technologies, Inc, Available from URL:, Accessed 15 February 2009.
51. Wajberg E, Miyazaki Y, Triplitt C, Cersosimo E, Defronzo RA. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy non-diabetic subjects. Diabetes Care 2004, 27:2868-2874.
52. Iyer H, Khedkar A, Verma M, Krishnamurthy S, Anand Arun. A dose escalation study of IN-105 (insulin analogue) tablets in type 2 diabetes mellitus subjects. 2009, Poster #442-P, ADA,, New Orleans
53. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Control Release 2000, 65:261-269.
54. Leung FK, Jing Li, Song Y, Wong S, Hornig W, Leung E. Improved Efficacy of Intesulin (Oral Insulin) Formulated with Unmodified Regular Insulin in Normal Rats 2005, San Diego, American Diabetes Association, 65th Scientific Sessions,
55. Kidron M, Raz I, Wolfensberger M, Schwob H, Schruefer C. Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin in Healthy Subjects 2008, San Francisco, American Diabetes Association, 68th Scientific Sessions,
56. Schwartz S, Geho B, Rosenberg L, Lau J. Single-blind, Placebo-controlled, Dose-ranging Trial of Oral HDV-insulin in Patients with Type 2 Diabetes Mellitus 2008, San Francisco, American Diabetes Association, 68th Scientific Sessions,
57. Whitelaw CD, Kelly CA, Ironmonger W, Cunliffe C, New R, Phillips JN. Absorption of Orally Ingested Insulin in Human Type 1 Diabetic Subjects: Proof of Concept Study 2005, San Diego, American Diabetes Association, 65th Scientific Sessions,
58. Lasch F, Schönbrunner E. Weitere Untersuchungen über die enterale Insulinresorption. Über den Schutz des Insulins gegen Trypsin. Naunyn Schmiedeberg Arch Pharmacol 1936, 182:452-458.
59. Repeat dosing data for capsulin, phase II in type 2 diabetes. 2008, European Association for the Study of Diabetes (EASD), Scientific Sessions,, Rome
60. Daniel D, Wegmann DR. Protection of non-obese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996, 93:956-960.
61. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in non-obese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991, 88:10252-10256.
62. Saï P, Rivereau AS. Prevention of diabetes in the non-obese diabetic mouse by oral immunological treatments: comparative efficiency of human insulin and two bacterial antigens, lipopolysaccharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. Diabet Metab 1996, 22:341-348.
63. Polanski M, Melican NS, Zhang J, Weiner HL. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 1997, 10:339-346.
64. Chaillous L, Lefèvre H, Thivolet C. Oral insulin administration and residual β-cell function in recent onset type 1 diabetes: a multicentre randomized controlled trial. Lancet 2000, 356:545-549.